FDA records linked by MedtechLedger show Dixi Medical, listed at an address in Marchaux-Chaudefontaine, France, as the applicant on a traditional 510(k) for the SEEG-Tx® System (STX-SYS-001). The filing carries product code GXD, regulation number 882.4400, device class 2 and the Neurology advisory committee, with a decision of substantially equivalent dated October 29, 2026. The company's own pages describe SEEG-Tx® as a proprietary radiofrequency ablation system developed for use with its SEEG electrodes. [1][3][4]
The cleared filing and its scope
K260337 was received February 2, 2026 and decided October 29, 2026 as substantially equivalent under a traditional review, with a summary statement and no third-party review. The record lists the applicant as Dixi Medical, country code FR, and the device as the SEEG-Tx® System (STX-SYS-001). The associated classification entry places the device under product code GXD, regulation 882.4400, device class 2, in the neurology specialty. [1][2]
The supplied collection contains one linked record, a 510(k) with a substantially equivalent decision, and the record sample holds that same single entry. These counts describe the filings retrieved as of the snapshot date and are not a measure of total company sales, total portfolio or safety performance. No recall records appear in the retrieved sample. [1][9]
What the manufacturer says the system does
Dixi Medical's product page describes SEEG-Tx® as the first FDA-cleared power-controlled radiofrequency ablation system designed specifically for use with DIXI medical SEEG electrodes, allowing clinicians to move from localization to intervention within the same SEEG workflow using electrodes already implanted for diagnostic evaluation. The same page states the system was developed for the treatment of drug-resistant focal epilepsy using implanted DIXI medical SEEG electrodes. [3][5]
A company news post dated November 2, 2026 announces the launch and describes targeted radiofrequency ablation using the same electrodes already implanted to identify the epileptogenic zone, integrating lesioning into the existing SEEG-guided workflow. The product page states the system is currently available only in the United States. These characterizations are the manufacturer's published statements. [4][5][6]
Submission history and company background
A company post dated February 5, 2026 announced that a 510(k) for SEEG-Tx®, described there as its first proprietary thermocoagulation system, had been filed that week with FDA. The later FDA record for K260337 shows receipt on February 2, 2026, and the November 2026 announcement describes the cleared system as a radiofrequency ablation system. [1][4][8]
Dixi Medical's website states that the company has been a reference in the SEEG field for over 50 years and describes its solutions as developed in collaboration with physicians. The company describes itself as a worldwide leader in intracranial electrodes for epilepsy diagnosis and treatment. These are company-published descriptions rather than independently verified findings. [4][7]
Support and contact channels
Company pages state that its team works with neurosurgeons, neurologists and biomedical engineers, with technical support and guidance for planning and execution of SEEG procedures, and list a French telephone number and email addresses for general and quality inquiries. The FDA record lists the applicant address as 2a Rte. De Pouligney Chaudefontaine, 25640 Marchaux-Chaudefontaine, France; that filing address is not treated here as a verified headquarters. [1][4][5]

